stoxline Quote Chart Rank Option Currency Glossary
Entrada Therapeutics, Inc. (TRDA)
14.23  0.87 (6.51%)    12-08 16:00
Open: 13.27
High: 14.46
Volume: 85,598
Pre. Close: 13.36
Low: 12.71
Market Cap: 474(M)
Technical analysis
2023-12-08 4:46:32 PM
Short term     
Mid term     
Targets 6-month :  20.53 1-year :  23.98
Resists First :  17.57 Second :  20.53
Pivot price 13.71
Supports First :  13.35 Second :  10.75
MAs MA(5) :  13.81 MA(20) :  14.36
MA(100) :  15.17 MA(250) :  14.54
MACD MACD :  -0.5 Signal :  -0.5
%K %D K(14,3) :  47.6 D(3) :  45.8
RSI RSI(14): 49.5
52-week High :  21.39 Low :  9.31
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ TRDA ] has closed below upper band by 41.7%. Bollinger Bands are 64.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 11 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 14.47 - 14.54 14.54 - 14.61
Low: 12.56 - 12.63 12.63 - 12.69
Close: 14.11 - 14.23 14.23 - 14.35
Company Description

Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Headline News

Wed, 29 Nov 2023
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Entrada Therapeutics, Inc. - TRDA - PR Newswire

Mon, 27 Nov 2023
HC Wainwright Adjusts Entrada Therapeutics' Price Target to $20 From $25, Maintains Buy Rating -

Fri, 24 Nov 2023
How Will the Market React to Entrada Therapeutics Inc (TRDA) Stock Getting a Bearish Rating - InvestorsObserver

Thu, 23 Nov 2023
Entrada (TRDA) Down on FDA Maintaining Clinical Hold on DMD Drug - Yahoo Finance

Thu, 23 Nov 2023
EXEL: 3 Biotech Stocks to Buy to Help the Health of Your Portfolio -

Wed, 22 Nov 2023
Why Is Neuromuscular Disease Focused Entrada Therapeutics (TRDA) Shares Trading Lower Today? - Entrada Th - Benzinga

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 33 (M)
Shares Float 15 (M)
Held by Insiders 14.9 (%)
Held by Institutions 74.9 (%)
Shares Short 1,660 (K)
Shares Short P.Month 1,650 (K)
Stock Financials
EPS -0.7
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 7.4
Profit Margin -25 %
Operating Margin 32 %
Return on Assets (ttm) -5.6 %
Return on Equity (ttm) -9.1 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 2.61
EBITDA (p.s.) -0.93
Qtrly Earnings Growth 0 %
Operating Cash Flow 117 (M)
Levered Free Cash Flow 124 (M)
Stock Valuations
PE Ratio -20.33
PEG Ratio 0
Price to Book value 1.92
Price to Sales 5.44
Price to Cash Flow 4.07
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android